Get Your Personalized Supplement StackSupplement Stack Quiz

Oligopin

Also known as: pine bark extract, French maritime pine bark extract, Oligopin

Overview

Oligopin is a standardized extract derived from the bark of the French maritime pine tree (Pinus pinaster), specifically formulated to contain a high concentration of low molecular weight procyanidins, including catechin and epicatechin oligomers. These compounds are potent antioxidants and contribute to the extract's potential anti-inflammatory and endocrine-modulating effects. It is primarily investigated for its applications in cardiometabolic health and conditions like polycystic ovary syndrome (PCOS). While rich in beneficial polyphenolic compounds, current research indicates a moderate level of maturity, with several randomized controlled trials (RCTs) and meta-analyses available. However, the evidence for significant clinical benefits, particularly in improving cardiometabolic risk factors or hormonal regulation in PCOS, remains mixed or inconclusive. Oligopin is generally considered safe with a favorable side effect profile.

Benefits

Current research on Oligopin, particularly in the context of cardiometabolic health and PCOS, has yielded mixed and largely inconclusive results regarding significant clinical benefits. A double-blind, randomized controlled trial involving 80 women with PCOS found that 3 months of Oligopin supplementation did not significantly improve cardiometabolic risk factors such as insulin, fasting glucose, lipid profiles, or hs-CRP compared to placebo. Similarly, a recent systematic review and meta-analysis on pine bark extracts, including Oligopin, reported inconsistent and generally non-significant effects on various cardiometabolic risk factors. While some studies have explored its potential to modulate hormonal markers in PCOS, such as testosterone and SHBG, these effects have not reached statistical significance in the cited RCT. Ongoing research is investigating its impact on ovarian morphology in PCOS, but definitive clinical benefits for this population are not yet established. Overall, the evidence does not currently support strong clinical benefits for Oligopin in these primary areas of investigation, with studies showing no significant effect sizes on key outcomes.

How it works

Oligopin exerts its effects primarily through its rich content of oligomeric proanthocyanidins (OPCs). Its main mechanism involves potent antioxidant activity, achieved by scavenging free radicals, which helps reduce oxidative stress in the body. It may also possess anti-inflammatory properties by modulating the production of various cytokines. In the context of cardiometabolic and endocrine systems, Oligopin's procyanidins are thought to influence endothelial function and lipid metabolism, potentially impacting cardiovascular health. Furthermore, there is an exploration into its ability to modulate hormonal pathways relevant to conditions like PCOS, although the exact mechanisms are still under investigation. The procyanidins are absorbed and metabolized in the gut, with systemic effects mediated by their metabolites.

Side effects

Oligopin is generally considered safe, with clinical trials reporting no major adverse events. Common side effects, defined as occurring in more than 5% of users, have not been reported at significant frequencies in clinical studies. Uncommon side effects (1-5% frequency) are limited to anecdotal reports of mild gastrointestinal discomfort. Rare side effects (less than 1% frequency) or serious adverse events have not been documented. Regarding drug interactions, no well-documented interactions exist, but caution is advised when taken concurrently with anticoagulants due to a theoretical potential for mild blood-thinning effects. There are no clearly established contraindications, but data on its use in pregnancy, breastfeeding, children, or individuals with severe comorbidities are limited, warranting caution in these populations.

Dosage

Due to a lack of consistent significant efficacy findings, a minimum effective dose for Oligopin has not been clearly established. Clinical trials typically utilize doses of 100 mg per day of Oligopin or an equivalent standardized pine bark extract. Doses up to 200 mg per day have been used safely in studies, suggesting this as a potential upper limit for daily intake, though a maximum safe dose is not well defined. Oligopin is usually administered orally, often in capsule or tablet form, and is standardized for its procyanidin content. It is generally recommended to take the supplement once daily, preferably with meals, as food intake may enhance the bioavailability of its active compounds. No specific cofactors are required for its absorption or efficacy.

FAQs

Does Oligopin improve cardiometabolic health?

Current evidence from randomized controlled trials and meta-analyses indicates no significant improvement in insulin sensitivity, lipid profiles, or inflammation markers with Oligopin supplementation.

Is Oligopin effective for PCOS symptoms?

A well-powered randomized controlled trial found no significant hormonal or metabolic improvements in women with PCOS after 3 months of Oligopin supplementation.

Is it safe to take Oligopin long-term?

While long-term data are limited, short-term use of Oligopin appears safe with minimal reported side effects, primarily mild gastrointestinal discomfort.

How soon can effects from Oligopin be expected?

Based on current research, there is no clear evidence of clinical benefits within 3 months of supplementation, and overall efficacy remains inconclusive.

Is Oligopin the same as Pycnogenol?

Oligopin is a specific proprietary pine bark extract, similar to Pycnogenol, but they may differ in their precise composition and standardization of active compounds.

Research Sources

https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.590392/pdf – This double-blind, placebo-controlled randomized controlled trial with 80 women with PCOS investigated the effects of Oligopin over 3 months. The study found that Oligopin did not significantly improve cardiometabolic risk factors such as insulin, fasting glucose, lipid profiles, or hs-CRP, nor did it significantly alter testosterone or SHBG levels, compared to placebo. The rigorous design and adequate sample size are strengths, though the duration was relatively short.
https://dro.deakin.edu.au/articles/journal_contribution/Does_supplementation_with_pine_bark_extract_improve_cardiometabolic_risk_factors_A_systematic_review_and_meta-analysis/28646273 – This systematic review and meta-analysis synthesized findings from multiple randomized controlled trials on pine bark extracts, including Oligopin, regarding their effects on cardiometabolic risk factors. The review reported mixed and generally non-significant effects on insulin resistance, lipid profiles, and inflammatory markers across the included studies. Strengths include comprehensive data synthesis, but limitations include heterogeneity among the studies analyzed.
https://onlinelibrary.wiley.com/doi/10.1155/2024/6479885 – This source refers to an ongoing study investigating Oligopin's effect on polycystic ovarian morphology (PCOM) in women with PCOS. As an ongoing study, its results are pending, meaning that clinical implications regarding Oligopin's potential benefits for ovarian morphology are not yet clear or established.